CVSA Covista Inc. Forecast, Technical & Fundamental Analysis

CVSA in downward trend: price expected to drop as it breaks its higher Bollinger Band on August 27, 2026

CVSA broke above its upper Bollinger Band on August 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 50 similar instances where the stock broke above the upper band. In 37 of the 50 cases the stock fell afterwards. This puts the odds of success at 74%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CVSA turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 24 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

CVSA moved below its 50-day moving average on September 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CVSA crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on CVSA as a result. In 63 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +0.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVSA advanced for three days, in 290 of 387 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 171 of 263 cases where CVSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CVSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.922) is normal, around the industry mean (2.851). P/E Ratio (16.577) is within average values for comparable stocks, (48.823). Projected Growth (PEG Ratio) (0.915) is also within normal values, averaging (1.351). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.325) is also within normal values, averaging (27.566).